Stocktoria
Altimmune, Inc. ALT
Altimmune, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 | $4.4M | $8.2M | $5.8M | $10.3M | $10.7M | $3.2M |
| R&D expense | $66.4M | $82.2M | $65.8M | $70.5M | $74.5M | $49.8M | $17.8M | $18.5M | $18.4M | $7.2M |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M | -$54.8M | -$21.5M | -$42.8M | -$52.0M | -$11.1M |
| Interest expense | — | — | $35,000 | $8,000 | $5,000 | $9,421 | $2,244 | $297,090 | $162,139 | $38,499 |
| Income tax | -$681,000 | — | — | -$197,000 | — | -$5.4M | -$58,500 | -$6.1M | -$5.6M | $0 |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M | -$97.1M | -$49.0M | -$20.5M | -$39.2M | -$46.4M | -$11.1M |
| EPS (diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | — | — | — | $2.95 |
| Operating cash flow | -$67.5M | -$79.8M | -$75.8M | -$62.6M | -$78.2M | -$34.3M | -$9.6M | -$9.4M | -$20.2M | -$6.4M |
| Free cash flow | -$67.5M | — | -$75.9M | -$62.7M | -$90.4M | -$34.5M | -$9.6M | -$10.4M | -$20.3M | -$6.5M |
| Cash & equivalents | $43.8M | $36.9M | $135.1M | $111.1M | $190.3M | $115.9M | $9.0M | $33.7M | $8.8M | $2.9M |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M | $245.1M | $54.1M | $54.8M | $63.0M | $38.4M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M | $19.2M | $8.5M | $6.4M | $14.4M | $6.2M |
| Shareholders' equity | $224.9M | $123.5M | $194.1M | $185.3M | $199.1M | $225.9M | $45.5M | $48.3M | $39.4M | $32.2M |
Growth · year-over-year · Revenue CAGR -38.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +105.0% | -95.3% | — | -101.5% | -46.1% | +41.1% | -43.8% | -3.8% | +231.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.